Skip to main content

Biomarker Development for Postoperative Cognitive Impairment in the Elderly


Start Date
End Date
Total Funding
€ 7 743 063
Funding Programme
European Countries Involved

Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the cognitive decline in Alzheimer dementia. POD is strongly associated with subsequent dementia after 3.2 and 5.0 years of follow-up: odds ratio = 12.52 [95% CI, 1.86-84.21] corrected for baseline dementia, severity of illness, age. In an aging society like the EU, the socioeconomic implications of POD/POCD are therefore profound. At present no treatment exists and there are no established molecular or imaging biomarkers that allow risk and clinical outcome prediction. We will establish valid biomarkers panels for risk and clinical outcome prediction of POD/POCD in N=1200 surgical patients according to the regulatory requirements of the European Medicines Agency. Thus, a valuable database will be created not yet existing worldwide. Neuroimaging investigations, which directly provide information on brain structure/function, will include structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), arterial spin labelling (ASL), functional magnetic resonance imaging with simultaneous electrophysiology (fMRI/EEG) and glutamate MR-spectroscopy (MRS). These investigations will be complemented by genetic/gene expression analyses (sequencing of cholinergic candidate genes/corresponding transcripts) and analyses of plasma and cerebrospinal fluid markers (inflammatory/metabolic). Supported by bioinformatics approaches, integration of neuroimaging data with knowledge from molecular biomarkers (multivariate expert system) is expected to allow patient stratification. This will greatly support decision-making before surgical intervention (balancing benefits and risks) as well as the development of novel therapies in POD/POCD.

Project partners

Charite - Universitaetsmedizin Berlin
Universitair Medisch Centrum Utrecht
Cambridge University Hospitals Nhs Foundation Trust
Max Delbrueck Centrum Fuer Molekulare Medizin In Der Helmholtz-Gemeinschaft (Mdc)
Consiglio Nazionale Delle Ricerche Universite Du Luxembourg
Atlas Biolabs Gmbh
Pharmaimage Biomaker Solutions Gmbh
Immundiagnostik Ag
Alta Ricerca E Sviluppo In Biotecnologie Srlu
Cellogic Gmbh
Physikalisch-Technische Bundesanstalt

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).